Home > Insider Trading > Filing (0001209191-14-043444)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1459266	Zs Pharma Inc.	ZSPH	Pharmaceutical Preparations (2834)	263305698

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1198330	P Guy Nohra	508 Wrangler Drive, Suite 100 Coppell TX 75019		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-06-23	3,030,090	$0.00	3,030,090	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2014-06-23	200,000	$18.00	3,230,090	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2014-06-23	2,849,703	$0.00	2,849,703	$0.00
Common Stock	Series D Preferred Stock	Disposition	2014-06-23	180,387	$0.00	180,387	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Consists of (a) 2,849,703 shares of common stock which were issued upon conversion of 2,849,703 shares of Series C Preferred stock and (b) 180,387 shares of common stock which were issued upon conversion of 180,387 shares of Series D Preferred stock.
Converted upon consummation of the initial public offering on a one-to-one conversion basis.
Alta Partners VIII, L.P. ("APVIII") is the holder of record of the securities. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. Guy Nohra, Daniel Janney and Farah Champsi are managing directors of APMVIII and exercise shared voting and investment power with respect to the shares owned by APVIII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.
APVIII purchased 200,000 shares of common stock in the initial public offering.
Consists of (a) 2,849,703 shares of common stock which were issued upon conversion of 2,849,703 shares of Series C Preferred stock, (b) 180,387 shares of common stock which were issued upon conversion of 180,387 shares of Series D Preferred stock, and (c) 200,000 shares of common stock purchased in the initial public offering.